The global Bronchopulmonary Dysplasia Treatment Market is expected to garner a market value of USD 385.6 million in 2023 and is expected to accumulate USD 700.2 million by registering a CAGR of 6.1% in the forecast period.
The market growth is attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe.
The market registered a CAGR of 5.0% in the historical period 2018 to 2022. Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants who received supplemental oxygen or mechanical ventilation.
It is also called respiratory distress syndrome. In addition, bronchopulmonary dysplasia also occurs in infants who experience abnormal lung development or had a pre-birth antenatal infection.
Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition causes serious complications during infancy and requires hospitalization and intensive medical care, during the first 2 years after birth.
The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.
The disease is caused by other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, which affects the development of the lungs.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles to market growth. Moreover, the high cost of treatment owing to the complex nature of the disease is another factor impeding the market growth.
Lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of the bronchopulmonary dysplasia treatment sector.
| Attributes | Details |
|---|---|
| Bronchopulmonary Dysplasia Treatment Market CAGR (2023 to 2033) | 6.1% |
| Bronchopulmonary Dysplasia Treatment Market Size (2023) | USD 385.6 million |
| Bronchopulmonary Dysplasia Treatment Market Size (2033) | USD 700.2 million |
The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period, reaching a total of USD 700.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.0%.
The prevalence of the COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.
Most end-user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favoring the growth of the market in the assessment period.
According to the Airway estimates, in Europe and the United States, up to 160,000 infants are at high risk for the development of BPD collectively, each year.
Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and a raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of the bronchopulmonary dysplasia treatment market over the forecast period.
Growing research and development activities by pharmaceutical companies to develop innovative treatment options for bronchopulmonary dysplasia boost the market in near future.
Companies are focusing on the development of novel treatment options for bronchopulmonary dysplasia for faster action and quick relief than the conventional dosage forms.
For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.
On the other hand, research is developing stem cell therapy for novel therapeutic modalities for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in preterm infants.
| Countries | Market Share (2022) |
|---|---|
| United States | 35.6% |
| Germany | 7.8% |
| Japan | 3.0% |
North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased awareness about bronchopulmonary dysplasia, and high treatment rates are expected to drive the growth of the market over the forecast period.
Advancements in the healthcare sector along with continuous research and development in treating bronchopulmonary dysplasia is favoring market growth, especially in the United States. Thus, due to the reasons mentioned above, North America held 41.2% market share in 2022.
| Country | United Kingdom |
|---|---|
| Market CAGR (2023 to 2033) | 5.2% |
Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region.
In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.
The strong presence of healthcare sectors in the Netherlands along with government policies working in the favor of childcare are accelerating the growth of the market. Thus, owing to the aforementioned reasons, Europe possessed 37.2% market share in 2022.
| Countries | Market CAGR (2023 to 2033) |
|---|---|
| China | 9.1% |
| India | 7.4% |
With 73.6 million live births in Asia Pacific and a preterm rate of <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown over time. A rise in awareness toward the treatment of the disease and an increase in healthcare expenditure is expected to boost the market growth.
A large patient pool along with government programs and initiatives are the key factors influencing the market growth in Asia Pacific. Thus, Asia Pacific procured a 35% market share in 2022.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as the effectiveness of drugs and more commonly used therapy.
In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy held a 35.8% market share in 2022.
Based on end-users, the global market is classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.
Most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals possessed a 47.5% market share in 2022.
Key bronchopulmonary dysplasia treatment start-ups are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.
Attention was drawn to modifying treatment regimens in accordance with the unique patient features and severity of the condition. Approaches to personalized medicine aimed to improve results and lessen treatment adverse effects.
The pathophysiology of bronchopulmonary dysplasia was extensively researched, and possible treatment targets were found in large part by universities and research organizations. These findings helped to design novel therapeutic strategies and enhance patient outcomes.
The market is forecast to register a CAGR of 6.1% through 2033.
The market is valued to reach USD 700.2 million by 2033.
The global market advanced at a 5% HCAGR from 2018 to 2022.
The market to secure a valuation of USD 385.6 million in 2023.
The supplemental oxygen supplement therapy sector comprises 35.8% of the market share.
The hospital category garners 47.5% of the market.
China market is set to expand at a 9.1% CAGR.
| Expected Market value in 2023 | USD 511 Million |
|---|---|
| Expected Market value in 2033 | USD 932.54 Million |
| Growth Rate (2023 to 2033) | 6.2% |
Explore Therapy Area Insights
View Reports
Bronchopulmonary Dysplasia Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
